FDA approves pembrolizumab with chemotherapy for …
WEBSep 17, 2024 · Patients were randomized (1:1) to receive either pembrolizumab for up to 2 years in combination with pemetrexed and platinum-based chemotherapy for up to 6 cycles (n=222) or pemetrexed and ...
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative …
WEBJul 20, 2022 · Pembrolizumab monotherapy has shown durable antitumor activity in advanced triple-negative breast cancer, 6-9 particularly as first-line therapy, with improved clinical responses observed among...
FDA approves pembrolizumab as adjuvant treatment for non …
WEBOn January 26, 2023, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB...
New Pembrolizumab Data Presented at ESMO Show Promise in a …
WEB5 days ago · Multiple new trial results have been presented at the European Society for Medical Oncology (ESMO) Congress 2024 supporting the use of pembrolizumab (Keytruda; Merck) in a variety of cancer types, including breast cancer, melanoma, hepatocellular carcinoma, and cervical cancer. Pembrolizumab is an anti-programmed death receptor 1 (PD-1) therapy ...
FDA approves neoadjuvant/ adjuvant pembrolizumab for …
WEBOn October 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of...
Pembrolizumab improves outcomes in high-risk bladder cancer
WEBSep 16, 2024 · NCI Press Office. 240-760-6600. Adjuvant pembrolizumab helps people with muscle-invasive bladder cancer remain cancer-free longer than observation alone. Credit: Terese Winslow/National Cancer Institute. Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk ...
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined …
WEBMay 5, 2021 · KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-approved test.
Pembrolizumab to Prevent Early-Stage Melanoma Recurrence
WEBOct 13, 2021 · Patients who received the immunotherapy pembrolizumab (Keytruda) after surgery to remove high-risk stage II melanomas were less likely to have the cancer come back than those who received no post-surgical treatment, new study results show.
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy …
WEBJan 25, 2023 · Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung …
WEBJun 3, 2023 · Among patients with resectable, early-stage NSCLC, neoadjuvant pembrolizumab plus chemotherapy followed by resection and adjuvant pembrolizumab significantly improved event-free survival, major...
Skip to content